Teva Pharmaceutical Industries Limited (TEVA) Discusses on Olanzapine LAI (TEV-‘749)

Operator

Welcome to the Olanzapine LAI TEV-‘749 Phase III SOLARIS Data Presentation Conference Call. My name is Elliot, and I’ll be coordinating your call today. [Operator Instructions].

I would now like to hand over to Christopher Stevo. Please go ahead.

Christopher Stevo
Senior Vice President of Investor Relations & Competitive Intelligence

Thank you, Elliot. Good morning and good afternoon, everyone. Thank you for joining us for this call. In a moment, I’ll introduce — sorry, pass you on to my colleague, Eric Hughes, who will introduce the other speakers. But I just want to let you know we’ll be making forward-looking statements during today’s call, and we undertake no obligation to update those statements after today’s call. And if you have any further questions on our forward-looking statements, please see the appropriate sections of our SEC filings under forms 10-Q and 10-K.

And with that, my colleague, Dr. Eric Hughes, the floor is yours.

Eric Hughes
Executive VP of Global R&D and Chief Medical Officer

Thank you, Chris, and thank you for everyone joining today to talk about our SOLARIS Phase III data, safety and efficacy that we presented recently at the Psych Conference in San Diego.

Moving forward, before we get talking